As tumor MLH1 promoter methylation and BRAFV600E mutation are proven predictors of a negative MMR mutation status (21-24), we evaluated their status in all microsatellite-instable cancers prior to germline analysis of MMR genes. This evidence concerns the gene MRC1 and neoplasm.